Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer

被引：0
作者：
Zheqiong Tan
Pragney Deme
Keerti Boyapati
Britt S. R. Claes
Annet A. M. Duivenvoorden
Ron M. A. Heeren
Caitlin M. Tressler
Norman James Haughey
Kristine Glunde
机构：
[1] Johns Hopkins University School of Medicine,Russell H. Morgan Department of Radiology and Radiological Science, Division of Cancer Imaging Research
[2] Tongji Medical College,Department of Medical Laboratory, The Central Hospital of Wuhan
[3] Huazhong University of Science and Technology,Department of Neurology
[4] Johns Hopkins University School of Medicine,Maastricht MultiModal Molecular Imaging Institute
[5] Maastricht University,Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism
[6] Maastricht University,Department of Psychiatry
[7] Johns Hopkins University School of Medicine,Sidney Kimmel Comprehensive Cancer Center
[8] Johns Hopkins University School of Medicine,Department of Biological Chemistry
[9] Johns Hopkins University School of Medicine,undefined
来源：
Breast Cancer Research | / 25卷
关键词：
PNPLA8; Breast cancer; Triple negative; Phospholipid; Metabolism reprogramming; Eicosanoids; Migration; Invasion; Proliferation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Key Role of Hyaluronan Metabolism for the Development of Brain Metastases in Triple-Negative Breast Cancer
    Hamester, Fabienne
    Stuerken, Christine
    Legler, Karen
    Eylmann, Kathrin
    Moller, Katrin
    Rossberg, Maila
    Gorzelanny, Christian
    Bauer, Alexander T.
    Windhorst, Sabine
    Schmalfeldt, Barbara
    Laakmann, Elena
    Muller, Volkmar
    Witzel, Isabell
    Oliveira-Ferrer, Leticia
    CELLS, 2022, 11 (20)
  • [42] Targeting the tumor immune microenvironment: GPCRs as key regulators in triple-negative breast cancer
    Wang, Chengyi
    Liu, Yanyan
    Zhang, Ru
    Gong, Hao
    Jiang, Xinnong
    Xia, Shuai
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 147
  • [43] Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer
    Zhang, Hao
    Zhu, Shuangli
    Zhou, Haiting
    Li, Rui
    Xia, Xiaohui
    Xiong, Huihua
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [44] MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration
    Song, Guo-qing
    Zhao, Yi
    TUMOR BIOLOGY, 2015, 36 (07) : 5001 - 5009
  • [45] A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer
    Mineva, Nora D.
    Pianetti, Stefania
    Das, Sonia G.
    Srinivasan, Srimathi
    Billiald, Nicolas M.
    Sonenshein, Gail E.
    PHARMACEUTICS, 2024, 16 (04)
  • [46] FOSL1 is a key regulator of a super-enhancer driving TCOF1 expression in triple-negative breast cancer
    He, Qingling
    Hu, Jianyang
    Huang, Hao
    Wu, Tan
    Li, Wenxiu
    Ramakrishnan, Saravanan
    Pan, Yilin
    Chan, Kui Ming
    Zhang, Liang
    Yang, Mengsu
    Wang, Xin
    Chin, Y. Rebecca
    EPIGENETICS & CHROMATIN, 2024, 17 (01)
  • [47] MicroRNA-182 promotes proliferation and metastasis by targeting FOXF2 in triple-negative breast cancer
    Zhang, Xingzeng
    Ma, Genshun
    Liu, Jianchao
    Zhang, Yajun
    ONCOLOGY LETTERS, 2017, 14 (04) : 4805 - 4811
  • [48] miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN
    Fang, Hong
    Xie, Jiping
    Zhang, Min
    Zhao, Ziwei
    Wan, Yi
    Yao, Yongqiang
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (03): : 953 - 961
  • [49] A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells
    Koh, Minsoo
    Lee, Jong-Cheol
    Min, Changhee
    Moon, Aree
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (08) : 2305 - 2313
  • [50] Downregulation of RIP140 in triple-negative breast cancer inhibits the growth and proliferation of cancer cells
    Yu, Xiao-Hong
    Xue, Xiaodong
    Zhu, Xun
    Li, Xia
    ONCOLOGY LETTERS, 2018, 15 (06) : 8784 - 8788
12345